Identifying effect modifiers of systemic hydrocortisone treatment initiated 7-14 days after birth in ventilated very preterm infants on long-term outcome: secondary analysis of a randomised controlled trial.
Nienke Marjolein HalbmeijerMichel SonnaertRenate M SwarteCorine Koopman-EsseboomMargriet van StuijvenbergSusanne Mulder-de TollenaerRatna N G B TanThilo MohnsEls BruneelKaterina SteinerBoris W KramerAnne DebeerMirjam M van WeissenbruchYoann MarechalHenry BlomKatleen PlaskieMartin OffringaMaruschka P MerkusWes OnlandAleid G LeemhuisAnton H van Kaamnull nullPublished in: Archives of disease in childhood. Fetal and neonatal edition (2023)
This secondary analysis suggests that in infants <27 weeks' GA, systemic hydrocortisone may improve the outcome death or NDI, mainly driven by its component death. There was insufficient evidence for other selected candidate effect modifiers.